Objective: We examined the contribution of attention and executive cognitive processes to ADHD symptomatology in NF1, as well as the relationships between cognition and ADHD symptoms with functional outcomes. Methods: The study sample consisted of 141 children and adolescents with NF1. Children were administered neuropsychological tests that assessed attention and executive function, from which latent cognitive variables were derived. ADHD symptomatology, adaptive skills, and quality of life (QoL) were assessed using parent-rated questionnaires. Path analyses were conducted to test relationships among cognitive functioning, ADHD symptomatology, and functional outcomes. Results: Significant deficits were observed on all outcome variables. Cognitive variables did not predict ADHD symptomatology. Neither did they predict functional outcomes. However, elevated ADHD symptomatology significantly predicted functional outcomes. Conclusion: Irrespective of cognitive deficits, elevated ADHD symptoms in children with NF1 negatively impact daily functioning and emphasize the importance of interventions aimed at minimizing ADHD symptoms in NF1.
AnastasakiC.WooA. S.MessiaenL. M.GutmannD. H. (2015). Elucidating the impact of neurofibromatosis-1 germline mutations on neurofibromin function and dopamine-based learning. Human Molecular Genetics, 24, 3518–3528.
2.
BarkleyR. A. (1997). Behavioral inhibition, sustained attention, and executive functions: Constructing a unifying theory of ADHD. Psychological Bulletin, 121, 65–94.
3.
BrownJ. A.EmnettR. J.WhiteC. R.YuedeC. M.ConyersS. B.O’MalleyK. L.. . . GutmannD. H. (2010). Reduced striatal dopamine underlies the attention system dysfunction in neurofibromatosis-1 mutant mice. Human Molecular Genetics, 19, 4515–4528.
4.
BrownJ. A.XuJ.Diggs-AndrewsK. A.WozniakD. F.MachR. H.GutmannD. H. (2011). PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice. Experimental Neurology, 232, 333–338.
5.
CastellanosF. X.Sonuga-BarkeE. J. S.MilhamM. P.TannockR. (2006). Characterizing cognition in ADHD: Beyond executive dysfunction. Trends in Cognitive Sciences, 10, 117–123.
6.
CastellanosF. X.TannockR. (2002). Neuroscience of attention-deficit/hyperactivity disorder: The search for endophenotypes. Nature Reviews: Neuroscience, 3, 617–628.
7.
ChisholmA. K.AndersonV.PrideN. A.MalarbiS.NorthK. N.PayneJ. M. (2018). Social function and autism spectrum disorder in children and adults with neurofibromatosis type 1: A systematic review and meta-analysis. Neuropsychology Review, 28, 317–340.
8.
CoghillD. R.HaywardD.RhodesS. M.GrimmerC.MatthewsK. (2014). A longitudinal examination of neuropsychological and clinical functioning in boys with attention deficit hyperactivity disorder (ADHD): Improvements in executive functioning do not explain clinical improvement. Psychological Medicine, 44, 1087–1099.
9.
CoghillD. R.RhodesS. M.MatthewsK. (2007). The neuropsychological effects of chronic methylphenidate on drug-naive boys with attention-deficit/hyperactivity disorder. Biological Psychiatry, 62, 954–962.
10.
CohenJ. (1988). Statistical power analysis for the behavioral sciences (2nd ed.). Lawrence Erlbaum.
11.
ConnersC. K. (2000). Conner’s Continuous Performance Test II (CPT-II) Version 5.1 for windows. Multi-Health Systems Inc.
12.
ConnersC. K. (2008). Conners 3rd Edition. Toronto, Ontario: Multi-Health Systems Inc.
13.
DanckaertsM.Sonuga-BarkeE. J. S.BanaschewskiT.BuitelaarJ.DöpfnerM.HollisC.. . . CoghillD. (2010). The quality of life of children with attention deficit/hyperactivity disorder: A systematic review. European Child & Adolescent Psychiatry, 19, 83–105.
14.
EbyN. S.GriffithJ. L.GutmannD. H.MorrisS. M. (2019). Adaptive functioning in children with neurofibromatosis type 1: Relationship to cognition, behavior, and magnetic resonance imaging. Developmental Medicine & Child Neurology, 61, 972–978.
GarwoodM. M.BernackiJ. M.FineK. M.HainsworthK. R.DaviesW. H.Klein-TasmanB. P. (2012). Physical, cognitive, and psychosocial predictors of functional disability and health-related quality of life in adolescents with neurofibromatosis-1. Pain Research and Treatment, 2012, Article 75364.
17.
GrafA.LandoltM. A.MoriA. C.BoltshauserE. (2006). Quality of life and psychological adjustment in children and adolescents with neurofibromatosis type 1. The Journal of Pediatrics, 149, 348–353.
18.
GutmannD. H.FernerR. E.ListernickR. H.KorfB. R.WoltersP. L.JohnsonK. J. (2017). Neurofibromatosis type 1. Nature Reviews: Disease Primers, 3, Article 17004.
19.
JensenP. S.HinshawS. P.KraemerH. C.LenoraN.NewcornJ. H.AbikoffH. B.. . . VitielloB. (2001). ADHD comorbidity findings from the MTA Study: Comparing comorbid subgroups. Journal of the American Academy of Child & Adolescent Psychiatry, 40, 147–158.
20.
Klein-TasmanB. P.ColonA. M.BreiN.van der FluitF.CasnarC. L.JankeK. M.. . . WalkerJ. A. (2013). Adaptive behavior in young children with neurofibromatosis type 1. International Journal of Pediatrics, 2013, Article 690432.
21.
LehtonenA.HowieE.TrumpD.HusonS. M. (2012). Behaviour in children with neurofibromatosis type 1: Cognition, executive function, attention, emotion, and social competence. Developmental Medicine & Child Neurology, 55, 111–125.
22.
LiW.CuiY.KushnerS. A.BrownR. A.JentschJ. D.FranklandP. W.. . .SilvaA. J. (2005). The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1. Current Biology, 15, 1961–1967.
23.
ManlyT.AndersonV.Nimmo-SmithI.TurnerA.WatsonP.RobertsonI. H. (2001). The differential assessment of children’s attention: The Test of Everyday Attention for Children (TEA-Ch), normative sample and ADHD performance. The Journal of Child Psychology and Psychiatry, 42, 1065–1081.
24.
MortonJ.FrithU. (1995). Causal modeling: A structural approach to developmental psychopathology. In CicchettiD. V.CohenD. J. (Eds.), Developmental psychopathology (pp. 357–390). John Wiley.
25.
Neurofibromatosis Conference Statement. (1988). National institutes of health consensus development conference. Archives of Neurology, 45, 575–578.
26.
NiggJ. T.WillcuttE. G.DoyleA. E.Sonuga-BarkeE. J. S. (2005). Causal heterogeneity in attention-deficit/hyperactivity disorder: Do we need neuropsychologically impaired subtypes?Biological Psychiatry, 57, 1224–1230.
27.
PayneJ. M.ArnoldS. S.PrideN. A.NorthK. N. (2012). Does attention-deficit-hyperactivity disorder exacerbate executive dysfunction in children with neurofibromatosis type 1?Developmental Medicine & Child Neurology, 34, 898–904.
28.
PayneJ. M.BartonB.ShoresE. A.NorthK. N. (2013). Paired associate learning in children with neurofibromatosis type 1: Implications for clinical trials. Journal of Neurology, 260, 214–220.
29.
PayneJ. M.BartonB.UllrichN. J.CantorA.HearpsS. J. C.CutterG.. . . NorthK. N. (2016). Randomized placebo-controlled study of lovastatin in children with neurofibromatosis type 1. Neurology, 87, 2575–2584.
30.
PayneJ. M.HearpsS. J. C.WalshK. S.PaltinI.BartonB.UllrichN. J.. . . NorthK. N. (2019). Reproducibility of cognitive endpoints in clinical trials: Lessons from neurofibromatosis type 1. Annals of Clinical and Translational Neurology. doi.org/10.1002/acn3.50952.
31.
PayneJ. M.HymanS. L.ShoresE. A.NorthK. N. (2011). Assessment of executive function and attention in children with neurofibromatosis type 1: Relationships between cognitive measures and real-world behavior. Child Neuropsychology, 17, 313–329.
32.
PayneJ. M.PorterM. A.PrideN. A.NorthK. N. (2016). Theory of mind in children with neurofibromatosis type 1. Neuropsychology, 30, 439–448.
33.
PolanczykG.de LimaM. S.HortaB. L.BiedermanJ.RohdeL. A. (2007). The worldwide prevalence of ADHD: A systematic review and metaregression analysis. The American Journal of Psychiatry, 164, 942–948.
34.
ReynoldsC. R.KamphausR. W. (2004). Behavior assessment system for children (2nd ed.). AGS Publishing.
35.
SikoraD. M.VoraP.CouryD. L.RosenbergD. (2012). Attention-deficit/hyperactivity disorder symptoms, adaptive functioning, and quality of life in children with autism spectrum disorder. Pediatrics, 130(Suppl. 2), S91–S97.
36.
Sonuga-BarkeE.BitsakouP.ThompsonM. (2010). Beyond the dual pathway model: Evidence for the dissociation of timing, inhibitory, and delay-related impairments in attention-deficit/hyperactivity disorder. Journal of the American Academy of Child & Adolescent Psychiatry, 49, 345–355.
37.
Sonuga-BarkeE. J. S. (2005). Causal models of attention-deficit/hyperactivity disorder: From common simple deficits to multiple developmental pathways. Biological Psychiatry, 57, 1231–1238.
38.
SteinM. A.SzumowskiE.BlondisT. A.RoizenN. J. (1995). Adaptive skills dysfunction in ADD and ADHD children. The Journal of Child Psychology and Psychiatry, 36, 663–670.
39.
TobertJ. A. (2003). Lovastatin and beyond: The history of the HMG-CoA reductase inhibitors. Nature Reviews: Drug Discovery, 2, 517–526.
40.
VarniJ. W.SeidM.KurtinP. S. (2001). PedsQL: Reliability and validity of the Pediatric Quality of Life Inventory version 4.0 generic core scales in healthy and patient populations. Medical Care, 39, 800–812.
41.
WehmeierP. M.SchachtA.BarkleyR. A. (2010). Social and emotional impairment in children and adolescents with ADHD and the impact on quality of life. Journal of Adolescent Health, 46, 209–217.
42.
WillcuttE. G.DoyleA. E.NiggJ. T.FaraoneS. V.PenningtonB. F. (2005). Validity of the executive function theory of attention-deficit/hyperactivity disorder: A meta-analytic review. Biological Psychiatry, 57, 1336–1346.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
